Problem

1. Over 260 million (76%) Americans are affected by mental health challenges.
2. Most frequent conditions: stress, ADHD, depression, anxiety, burnout, Alzheimer’s disease, and mild traumatic brain injuries.

Today’s solutions arrive too late

Most treatments focus on managing symptoms that have developed over the years.

America needs a new kind of intervention — the one that breaks the cycle of stress.

1. That supports the brain before it reaches a breaking point.
2. That changes how cognitive and emotional challenges begin, spread, and escalate.

Our Solution

We’ve engineered a breakthrough compound – Lithium Ascorbate Molecule.

This is a unique, proprietary formulation that serves as the foundation of our platform. Based on this molecule, we design targeted solutions to address specific brain and mental health conditions from stress and depression to to age-related cognitive changes.

Our long-term vision is to establish a new FDA-approved Medical Food category: Microdose Lithium for Brain & Mental Health.

Scientific Foundation → Molecule → Multiple Products → A New Category.

The Lithium Ascorbate Molecule

Every psychiatrist knows: lithium works.

Lithium carbonate, the most commonly used form of lithium, since 1949, is notorious for its high toxicity and associated side effects.

By reengineering this gold-standard molecule, we created a 21st-century mental health solution.

Our scientific team has discovered that lithium and vitamin C form a compound with extraordinary brain benefits, without unwanted side effects.

Backed by Years of Research

We’ve conducted 40+ studies and published 20+ peer-reviewed papers.

Full preclinical program - successfully completed.

40+ Scientific Research

1. Full GLP Preclinical Safety Package
2. Comparative Preclinical Efficacy Studies
3. Preclinical Neuroprotective Efficacy Studies
4. Human Observational Clinical Studies

Intellectual Property

1. US 10,849,878 LITHIUM ASCORBATE EXHIBITING ANTI-STRESS, ANXIOLYTIC AND ANTI-DEPRESSION ACTIVITY
2. US 10,456,373 LITHIUM ASCORBATE EXHIBITING ANTI-STRESS, ANXIOLYTIC AND ANTI-DEPRESSION ACTIVITY
3. US 11,219,641 USE OF LITHIUM ASCORBATE TO PREVENT AND TREAT ALCOHOLISM AND ALCOHOL INTOXICATION

How It Works?

Chronic stress impacts everything: mood, sleep, memory, decision-making, self-esteem.

The worse you feel, the harder it is to think clearly. Anxiety rises. Energy drops. Sleep suffers.

Stress feeds on that, forming a self-reinforcing loop that drags mental health down.

Lithium Ascorbate disrupts the stress cycle.

Preclinical studies show it blocks stress hormones, helping the brain stay calm and clear.

When stress is removed, everything else improves:

1. Lithium ascorbate blocks stress hormones, helping reduce the levels of depression by 39% and anxiety by 35% on the Hospital Anxiety and Depression Scale (HADS) in 60 days.
2. Increases brain-derived neurotrophic factor (BDNF) by 9%. BDNF is a neurotrophic agent crucial for thinking, memory, neuroplasticity, and neuronal survival. It promotes connections between neurons, boosting memory, ability to learn, and cognitive function.
3. Improves memory by lowering levels of anxiety, depression, and chronic stress — visual memory by 83%, auditory-verbal memory by 98%, and muscle memory by 83%.
4. Helps protect the brain from glutamate-induced stress after stroke, doubling neuron survival.
5. Under prolonged alcohol toxicity, it doubles neuron survival (18% vs 36%).

Why Now?

1. The mental & brain health supplement market is growing fast.The Global Mental Well-Being Supplements Market was valued at $11.48 billion in 2025 and is projected to grow at a CAGR* of 8.62% to reach a market value of $17.36 billion by 2030 [source].
2. The US Mental Well-Being Supplements Market accounts for approximately 40% of the global market, estimated at $4.83 billion in 2025, and expected to reach $7.30 billion by 2030.
3. The US brain health supplements market was estimated at $3.63 billion in 2025 and is expected to reach $6.90 billion by 2032, with a CAGR of 9.6% [source].

* — Compound Annual Growth Rate, shows the average annual growth rate of an investment over time, assuming steady growth.

We conservatively target to capture 0.8% of the US mental & brain health supplement market by 2030 — $130M.

Lithium Is Trending in Science and Media

Over the past two months, two of the world’s most prestigious scientific journals have published landmark research on lithium’s role in brain health.

1. On August 6, 2025, Nature released "Brain lithium deficiency in Alzheimer’s disease and reversal of pathology and memory deficits by lithium orotate in mouse models" (link), showing that lithium deficiency in the brain may underlie Alzheimer’s disease, and that lithium compounds can reverse memory loss in mice.
2. On June 9, 2025, The Lancet Psychiatry published "Lithium as a disease-modifying drug for bipolar disorder" (link), reviewing its unique long-term neuroprotective potential.
3. On August 9, 2025 The Washington Post (link) have called this research a potential “game-changer” for brain health.
4. On March 30, 2022, Molecules published “Lithium Ascorbate as a Promising Neuroprotector…” (link), showing that an organic lithium salt combining lithium with ascorbic acid has neuroprotective and antioxidant effects, suggesting a safer, more bioavailable form of lithium for brain health.

Our Current Stage

In the first stage, we built everything needed to scale: marketing and sales infrastructure.

What we've accomplished to date:

1. Completed the full R&D phase and preclinical research program.
2. Launched two products — Normotim and Lithium Ascorbate 1 mg.
3. Built strong acquisition channels: social media, Meta Ads, Google Ads, SEO, and PR.
4. Launched an affiliate program that now includes 1,336 influencers who regulary post and stream their reviews of our products across Instagram, TikTok, Amazon Storefront, and Amazon Live.
5. Established multiple sales channels: Amazon, TikTok Shop, and our own webstore Normotim.com.
6. Established partnerships with practitioners and clinics as a distribution channel, enabling trusted medical recommendations and building a foundation for clinical research and validation.

Traction & Unit Economics

Roadmap

Building a New Category: From Lithium Supplement to Medical Food

1. Funds raised in the SAFE round will be dedicated to launching new products and scaling online advertising and sales.
2. 2 additional products in the Lithium Ascorbate line are launching in 2026.
3. Formulations for 4 tailored supplements are currently in development, with a planned launch in 2026.
4. AgeBalance → Cognitive Aging & Burnout
5. AddictivaReset → Addiction & Impulse Control
6. NeuroRenew → Supports Neuroprotection & Cognitive Function
7. Mood & Appetite → Emotional Eating & Metabolic Dysregulation

By the end of 2026 we will have 2 product lines and 8 supplements in total.

Post-SAFE, we are entering R&D to establish the clinical research landscape for Lithium Ascorbate, laying the groundwork for human trials.

Following our Series A, we will initiate full-scale clinical studies to validate efficacy and safety on humans.

Our final goal is to work toward alignment with FDA regulatory requirements for medical food category.

Achieving this will position Normotim within the Medical Food category, a patent-protected segment, unlocking new regulatory pathways, market access, and scalable growth opportunities.

How This SAFE Round Works

This round is structured as a SAFE (Simple Agreement for Future Equity).

That means you’re not buying shares today but your investment converts into equity at the next priced financing round.

1. The company is raising $250K–$300K in this SAFE round.
2. The valuation cap is $7M. This is the maximum valuation at which your investment can convert into shares.
3. If the company grows and raises its next round at a higher valuation ($10M–$25M), your SAFE converts as if you invested earlier at a lower price per share.

In the illustrated scenarios, each $1 invested may convert into approximately $1.43–$3.57 in equity, depending on the company’s valuation at conversion.

Additionally, the SAFE includes an early-investor discount, meaning your investment converts into equity at a reduced price per share compared to new investors in the next round, rewarding you for investing early.

This means your SAFE investment will convert based on the company’s valuation at the next priced round, with potential growth equivalent to the illustrated percentage upside.

1. 1.43× → +43% potential upside
2. 2.14× → +114% potential upside
3. 3.57× → +257% potential upside

We reimagined lithium — now we’re scaling to bring it to millions.

Become part of the next mental health breakthrough — invest in Normotim.

👉 Check our Data room for more information

These statements have not been evaluated by the Food and Drug Administration. Normotim products are dietary supplements and are not intended to diagnose, treat, cure, or prevent any disease. References to scientific studies, publications, or ongoing research related to lithium or lithium compounds are provided for informational purposes only and do not imply that any Normotim product has been clinically proven to achieve similar outcomes. Any future regulatory pathways, including potential medical food or clinical applications, are subject to regulatory review and approval and may not be realized.